TFB Advisors LLC Invests $324,000 in DexCom, Inc. (NASDAQ:DXCM)

TFB Advisors LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,333 shares of the medical device company’s stock, valued at approximately $324,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Capital World Investors raised its stake in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Norges Bank acquired a new position in DexCom during the fourth quarter worth about $540,178,000. Artisan Partners Limited Partnership grew its stake in DexCom by 164.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares in the last quarter. Capital Research Global Investors raised its holdings in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after acquiring an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new position in DexCom in the 4th quarter worth approximately $231,773,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 0.0 %

Shares of DXCM traded down $0.05 during mid-day trading on Wednesday, hitting $110.79. 2,150,720 shares of the company’s stock were exchanged, compared to its average volume of 2,895,411. The stock’s 50-day moving average is $120.40 and its 200-day moving average is $125.22. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a market cap of $44.06 billion, a price-to-earnings ratio of 71.48, a P/E/G ratio of 2.71 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. On average, sell-side analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Redburn Atlantic assumed coverage on DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Citigroup raised their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group lifted their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, Raymond James increased their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.33.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders have sold 6,102 shares of company stock valued at $755,103 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.